Loading...
•
Sep 30
Bio-Techne Q1 2026 Earnings Report
Bio-Techne's first quarter fiscal 2026 results were released, showing a slight decrease in reported and organic revenue, while GAAP EPS increased and adjusted EPS remained flat.
Key Takeaways
Bio-Techne reported a 1% decrease in both reported and organic revenue for the first quarter of fiscal 2026, reaching $286.6 million. GAAP EPS increased to $0.24 from $0.21 in the prior year, while adjusted EPS remained stable at $0.42. The company completed the divestiture of its Exosome Diagnostics business and saw an increase in adjusted operating margin to 29.9% due to productivity and cost containment initiatives.
Reported and organic revenue for the first quarter decreased by 1% to $286.6 million.
GAAP earnings per share (EPS) increased to $0.24, up from $0.21 in the first quarter of 2025.
Adjusted EPS remained consistent at $0.42 compared to the prior year period.
Adjusted operating margin improved by 90 basis points to 29.9%, driven by productivity and cost containment efforts.
Bio-Techne
Bio-Techne
Bio-Techne Revenue by Segment
Revenue by Segment
Protein Sciences Segment Revenue
CapyFin.comDiagnostics and Spatial Biology Segment Revenue
CapyFin.com Forward Guidance
Bio-Techne's forward-looking statements indicate a dynamic operating environment with both encouraging signs and persistent headwinds, while emphasizing the company's strategic positioning for long-term value.
Positive Outlook
- Encouraging signs of stabilization in the US academic end market.
- Continued strength from large pharmaceutical customers.
- ProteinSimple's analytical solutions extended its growth momentum.
- Spatial Biology stabilized and showed early signs of accelerating growth.
- Cell Therapy customers received Fast Track Designation by the FDA, enabling shortened clinical development and approval timelines.
Challenges Ahead
- Funding headwinds persisted for emerging biotech companies.
- Advancements in Cell Therapy resulted in short- and intermediate-term order timing headwinds for the GMP proteins business.
- The impact of the growing number of producers of biotechnology research products and related price competition.
- General economic conditions and currency exchange rate fluctuations pose risks.
- Uncertainties related to the funding and focus of research by the Company's customers.
Revenue & Expenses
Visualization of income flow from segment revenue to net income